Positive phase III results for Roche ’s satralizumab in neuromyelitis optica spectrum disorder published in the New England Journal of Medicine

Roche announced today that data from SAkuraSky, a pivotal phase III study of the investigational medicine satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD), were published in the 27 November 2019 online issue of the New England Journal of Medicine (NEJM).
Source: Roche Media News - Category: Pharmaceuticals Source Type: news